Software derives biomarkers designed to monitor respiratory disease.
Functional respiratory imaging company Fluidda secured clearance from the U.S. Food & Drug Administration (FDA) this week for its digital imaging platform, Broncholab. The product is designed to help providers visualize factors that can help diagnose respiratory disease.
“Functional respiratory imaging has been used in clinical trials for many years and has proven its value time and time again,” said Jan De Backer, Fluidda’s chief executive officer, in a statement. “Broncholab now extends these capabilities into clinical practice which is a tremendous step forward in our quest for better respiratory care.”
Used after a low-dose CT scan, Broncholab can derive several biomarkers, such as nodule and airway volume, trapped air pockets, and maps of ventilation. According to company information, it can also predict how drug particles are deposited throughout the lung when a patient breathes them in, helping to guide and maximize treatment options.
In addition to using high-resolution CT scans, the BronchoLab system incorporates digital image processing, 3D modeling, and computational airflow simulations to offer clinically relevant information about perfusion in various lung regions.
The hope, De Backer added in the company statement, is that BronchoLab will be able to improve the understanding of respiratory illnesses, better preparing the healthcare system for global outbreaks of lung diseases, much like the current COVID19 pandemic.
Could Virtual Non-Contrast Images from Photon-Counting CT Reduce Radiation Dosing with CCTA?
March 28th 2024Emerging research on coronary artery calcium scoring for the assessment of coronary artery disease (CAD) suggests the use of virtual non-contrast images from photon-counting CT may lead to a nearly 20 percent reduction in radiation dosing.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Mobile C-Arm Device that May Accelerate Fluoroscopic and 3D CT Imaging
March 21st 2024Offering ease of mobility and self-driving capabilities, the Ciartic Move C-arm device reportedly reduces the stress and potential for error associated with manual repositioning during intraoperative imaging with computed tomography and fluoroscopy.